$54.99
CJC-1295 No DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids with strategic modifications to enhance enzymatic stability. In research settings, it is investigated for its ability to bind GHRH receptors on pituitary somatotroph cells, stimulate pulsatile growth hormone secretion, activate downstream IGF-1 production, and influence hypothalamic-pituitary-somatotropic axis function, making it a subject of interest in studies on GH secretion dynamics, endocrine rhythm regulation, and anabolic signaling pathways.
All products sold on this website are intended for research and identification purposes only and are not intended for human dosing, injections, or ingestion. These products are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for legitimate laboratory research and not for human or animal consumption.
CJC-1295 No DAC is a modified GHRH(1-29) analog incorporating four amino acid substitutions at positions 2, 8, 15, and 27 designed to confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation while preserving receptor binding affinity. Unlike the DAC-modified version with extended half-life, this variant maintains a shorter duration of action (approximately 30 minutes), enabling amplification of physiologic GH pulse patterns rather than sustained elevation. Research models examine its effects on pituitary GHRH receptor activation, growth hormone secretagogue activity, IGF-1 pathway stimulation, circadian GH rhythm modulation, and metabolic signaling in laboratory settings.
CJC-1295 W/O DAC has been extensively studied in neuroendocrine research, with investigations focusing on growth hormone secretion patterns, pituitary receptor pharmacology, metabolic effects, and somatotropic axis regulation in various experimental models. Studies examine its role in amplifying physiologic GH pulses without disrupting endogenous rhythms.
Key Areas of Research:
• GH secretion dynamics: Pulsatile GH release amplification, circadian rhythm preservation, peak amplitude enhancement, endogenous pulse pattern mimicry
• Receptor pharmacology: GHRH receptor binding affinity, somatotroph cell activation, cAMP signaling cascade, synergy with GH secretagogues
• IGF-1 pathway: Hepatic IGF-1 production stimulation, IGF-1 receptor activation, anabolic signaling cascade engagement
• Metabolic effects: Lipolysis promotion, nitrogen retention, protein synthesis enhancement, glucose metabolism modulation
Together, these investigations demonstrate CJC-1295 W/O DAC’s ability to enhance physiologic growth hormone secretion patterns. As a short-acting GHRH analog, it provides a research framework for examining hypothalamic-pituitary-somatotropic axis function, GH pulse dynamics, and growth factor signaling in diverse experimental paradigms.
Teichman et al., Clinical Endocrinology, 2006
Alba et al., The Journal of Clinical Endocrinology & Metabolism, 2005
Alba M. et al. (2005). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. The Journal of Clinical Endocrinology & Metabolism, 90(4):2171-2180.
Ionescu M. & Frohman L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Growth Hormone & IGF Research, 16(3):201-206
By accessing this website, you acknowledge and agree to the following:
All products sold on this site are intended strictly for laboratory research purposes only. These products are NOT for human consumption, medical use, or veterinary use.
By proceeding, you confirm that:
We do not make any claims regarding the safety, efficacy, or suitability of these products for any specific use.
Any misuse, improper handling, or use outside of intended research purposes is strictly prohibited and is the sole responsibility of the purchaser.
